LivaNova
- Market cap
- 4.18B
- P/E (TTM)i
- 22.40
- P/Bi
- 3.16
- EPSi
- -4.45
- Div yieldi
- 0.00%
- 52W posi
- 73%
Anonymous reader poll. Unscientific, not investment advice.
About LivaNova
LivaNova Plc is a global medical technology company, which engages in the development and delivery of therapeutic solutions for the benefit of patients, healthcare professionals, and healthcare systems. It operates through the following segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support (ACS). The Cardiopulmonary segment is involved in the design, development, manufacture, marketing and selling of cardiopulmonary products. The Neuromodulation segment is associated in the design, development, manufacture, marketing and selling of devices that deliver neuromodulation therapy for treating DRE and DTD. The ACS segment deals with the design, development, manufacture, marketing and selling of temporary life support products. The company was founded in 1987 and is headquartered in London, the United Kingdom.
- Founded
- 2015
- CEO
- Mr. Vladimir A. Makatsaria
- Employees
- 3,300
- Headquarters
- London, Greater London, United Kingdom of Great Britain and Northern Ireland (the)
- Fiscal year end
- 12-31
- Website
- livanova.com
Company profile
- Exchange
- US
- Symbol
- LIVN
- Market-cap rank
- #2263
- Listing date
- 1970-01-01
- Market cap
- 4.18B
- Float cap
- 4.16B
- Shares out
- 55.09M
- Float shares
- 54.84M
Sectors & themes
Quote time 2026-10-08 02:49:39 · For reference only, not investment advice and not tailored to your situation.